Posted Wednesday, October 8, 2008
This information is provided for research purposes only and does not constitute an endorsement by The Heuga Center. The brands listed are registered trademarks of their respective owners.
Do you want a treatment that is effective, easy to take and minimizes side effects? So do we. Join us in researching laquinimod, an investigational oral drug for MS.
As you may know, all six currently available treatments for relapsing-remitting multiple sclerosis (RRMS) require injections or infusions. While numerous studies have demonstrated these drugs are effective at decreasing the rate and severity of relapses, many are associated with negative side effects, such as flu-like symptoms, which can make living with RRMS that much harder.
Recognizing these challenges, Teva Neuroscience is now investigating a potential oral treatment option, laquinimod. Laquinimod is a pill, taken once-a-day, which has been given to more than 480 subjects in clinical trials. Results of a Phase II study of oral laquinimod recently published in the June 21, 2008 edition of The Lancet further demonstrated the experimental drug’s efficacy and tolerability.1 While the mechanism of action is still being confirmed, laquinimod is being tested to treat RRMS in a unique way – changing the means by which the immune system works rather than generally suppressing it.
If you have confirmed RRMS, are between the ages of 18 and 55, have never been treated with interferon medications (Avonex®, Betaseron® or Rebif®) and have had at least one relapse in the last 12 months (or two relapses in the last 24 months), the Bravo study may be right for you.
For more information, and to see if you may be eligible for the trial, please visit our Web site at www.tevaclinicaltrials.com or call us at 1-800-840-5601.
We look forward to hearing from you.
1Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371: 2085–92.